1BHF
P56LCK SH2 DOMAIN INHIBITOR COMPLEX
1BHF の概要
| エントリーDOI | 10.2210/pdb1bhf/pdb |
| 関連するBIRD辞書のPRD_ID | PRD_000406 |
| 分子名称 | T-LYMPHOCYTE-SPECIFIC PROTEIN TYROSINE KINASE P56LCK, INHIBITOR ACE-IPA-GLU-GLU-ILE (3 entities in total) |
| 機能のキーワード | sh2 domain, phosphorylation, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cytoplasm: P06239 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 12878.28 |
| 構造登録者 | Tong, L.,Warren, T.C.,Lukas, S.,Schembri-King, J.,Betageri, R.,Proudfoot, J.R.,Jakes, S. (登録日: 1998-06-08, 公開日: 1998-10-21, 最終更新日: 2024-11-13) |
| 主引用文献 | Tong, L.,Warren, T.C.,Lukas, S.,Schembri-King, J.,Betageri, R.,Proudfoot, J.R.,Jakes, S. Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding. J.Biol.Chem., 273:20238-20242, 1998 Cited by PubMed Abstract: The crystal structure of human p56(lck) SH2 domain in complex with an inhibitor containing the singly charged p-(carboxymethyl)phenylalanine residue (cmF) as a phosphotyrosine (Tyr(P) or pY) replacement has been determined at 1.8 A resolution. The binding mode of the acetyl-cmF-Glu-Glu-Ile (cmFEEI) inhibitor is very similar to that of the pYEEI inhibitor, confirming that the cmFEEI inhibitor has a similar mechanism of SH2 domain inhibition despite its significantly reduced potency. Observed conformational differences in the side chain of the cmF residue can be interpreted in terms of maintaining similar interactions with the SH2 domain as the Tyr(P) residue. The crystal structure of the free p56(lck) SH2 domain has been determined at 1.9 A resolution and shows an open conformation for the BC loop and an open phosphotyrosine binding pocket, in contrast to earlier studies on the src SH2 domain that showed mostly closed conformation. The structural information presented here suggests that the carboxymethyl-phenylalanine residue may be a viable Tyr(P) replacement and represents an attractive starting point for the design and development of SH2 domain inhibitors with better pharmaceutical profiles. PubMed: 9685372DOI: 10.1074/jbc.273.32.20238 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.8 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






